Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system.

Objectives To explore the association between palbociclib and related adverse events (AEs) in the real world through U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database